Business
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics
About this update from Context Therapeutics Inc.
[{"type":"text","content":"Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET\nPHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that an abstract regarding Context’s preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. Details of the presentation are as follows: Title: Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancerSession Category: ImmunologySession: PO.IM01.18 - Therapeutic Antibodies 1Abstract Number: 1865 / 4Presenter: Joseph Rucker, Ph.D., Integral MolecularDate and Time: April 17, 2023, 9:00 a.m. - 12:30 p.m. ETLocation: Section 25 For more information and to view the abstract, visit the AACR Annual Meeting website. On Monday, April 17, 2023, at 4:30 p.m. ET, Context will host a webinar with its management team and AACR presenter, Dr. Rucker, to discuss the results from this presentation and provide updates on the CTIM-76 preclinical program. Following the formal presentation, the Context team, along with Dr. Rucker, will be available for questions. To register for the webinar, please click here. Additionally, a replay of the webinar will be available on the Events page of the Investor Relations section of Context’s website, www.contexttherapeutics.com, for approximately 30 days after the webinar. About Claudin 6 and CTIM-76Claudin 6 (CLDN6) is differentially expressed on cancer cells with no or very low expression in normal, healthy tissue. CLDN6-enriched cancers include ovarian, endometrial, testicular, and gastric, among others. With the potential to reach a large patient population and selective expression on cancer cells, CLDN6 has emerged as an important drug target. CTIM-76 is a CLDN6 and CD3 bispecific antibody currently in preclinical development that is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while...